亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

医学 肿瘤科 乳腺癌 内科学 化疗 完全响应 打开标签 癌症 随机对照试验
作者
Jose Manuel Perez‐García,Javier Cortés,Manuel Ruíz‐Borrego,Marco Colleoni,Agostina Stradella,Begoña Bermejo,Florence Dalenc,Santiago Escrivá-de-Romaní,Lourdes Calvo,Nuria Ribelles,Frederik Marmé,Alfonso Cortés,Cinta Albacar,Géraldine Gebhart,Aleix Prat,Khaldoun Kerrou,Peter Schmid,Sofía Braga,Serena Di Cosimo,María Gión
出处
期刊:The Lancet [Elsevier BV]
卷期号:403 (10437): 1649-1659 被引量:34
标识
DOI:10.1016/s0140-6736(24)00054-0
摘要

Summary

Background

PHERGain was designed to assess the feasibility, safety, and efficacy of a chemotherapy-free treatment based on a dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer (EBC). It used an 18fluorine-fluorodeoxyglucose-PET-based, pathological complete response (pCR)-adapted strategy.

Methods

PHERGain was a randomised, open-label, phase 2 trial that took place in 45 hospitals in seven European countries. It randomly allocated patients in a 1:4 ratio with centrally confirmed, HER2-positive, stage I–IIIA invasive, operable breast cancer with at least one PET-evaluable lesion to either group A, where patients received docetaxel (75 mg/m2, intravenous), carboplatin (area under the curve 6 mg/mL per min, intravenous), trastuzumab (600 mg fixed dose, subcutaneous), and pertuzumab (840 mg loading dose followed by 420 mg maintenance doses, intravenous; TCHP), or group B, where patients received trastuzumab and pertuzumab with or without endocrine therapy, every 3 weeks. Random allocation was stratified by hormone receptor status. Centrally reviewed PET was conducted at baseline and after two treatment cycles. Patients in group B were treated according to on-treatment PET results. Patients in group B who were PET-responders continued with trastuzumab and pertuzumab with or without endocrine therapy for six cycles, while PET-non-responders were switched to receive six cycles of TCHP. After surgery, patients in group B who were PET-responders who did not achieve a pCR received six cycles of TCHP, and all patients completed up to 18 cycles of trastuzumab and pertuzumab. The primary endpoints were pCR in patients who were group B PET-responders after two treatment cycles (the results for which have been reported previously) and 3-year invasive disease-free survival (iDFS) in patients in group B. The study is registered with ClinicalTrials.gov (NCT03161353) and is ongoing.

Findings

Between June 26, 2017, and April 24, 2019, a total of 356 patients were randomly allocated (71 patients in group A and 285 patients in group B), and 63 (89%) and 267 (94%) patients proceeded to surgery in groups A and B, respectively. At this second analysis (data cutoff: Nov 4, 2022), the median duration of follow-up was 43·3 months (range 0·0–63·0). In group B, the 3-year iDFS rate was 94·8% (95% CI 91·4–97·1; p=0·001), meeting the primary endpoint. No new safety signals were identified. Treatment-related adverse events and serious adverse events (SAEs) were numerically higher in patients allocated to group A than to group B (grade ≥3 62% vs 33%; SAEs 28% vs 14%). Group B PET-responders with pCR presented the lowest incidence of treatment-related grade 3 or higher adverse events (1%) without any SAEs.

Interpretation

Among HER2-positive EBC patients, a PET-based, pCR-adapted strategy was associated with an excellent 3-year iDFS. This strategy identified about a third of patients who had HER2-positive EBC who could safely omit chemotherapy.

Funding

F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kylooe415完成签到,获得积分10
1秒前
bkagyin应助归尘采纳,获得10
4秒前
852应助归尘采纳,获得30
4秒前
在水一方应助归尘采纳,获得10
4秒前
wanci应助归尘采纳,获得10
4秒前
Owen应助归尘采纳,获得10
4秒前
万能图书馆应助归尘采纳,获得10
4秒前
眼睛大雨筠应助归尘采纳,获得20
4秒前
辇道增七应助归尘采纳,获得20
4秒前
lawrenceip0926完成签到,获得积分10
5秒前
在水一方应助归尘采纳,获得10
5秒前
无花果应助归尘采纳,获得10
11秒前
ding应助归尘采纳,获得10
11秒前
汉堡包应助归尘采纳,获得10
11秒前
充电宝应助归尘采纳,获得10
11秒前
牛牛牛应助归尘采纳,获得20
11秒前
NexusExplorer应助归尘采纳,获得10
11秒前
卡拉蜜儿应助归尘采纳,获得30
11秒前
打打应助归尘采纳,获得10
11秒前
YH应助归尘采纳,获得50
11秒前
领导范儿应助归尘采纳,获得30
11秒前
研友_VZG7GZ应助葛力采纳,获得10
11秒前
半城微凉发布了新的文献求助10
14秒前
可爱的函函应助归尘采纳,获得10
20秒前
Akim应助归尘采纳,获得10
20秒前
上官若男应助归尘采纳,获得10
20秒前
华仔应助归尘采纳,获得10
20秒前
领导范儿应助归尘采纳,获得10
20秒前
共享精神应助归尘采纳,获得10
20秒前
Owen应助归尘采纳,获得10
20秒前
ding应助归尘采纳,获得100
20秒前
Magali应助归尘采纳,获得30
20秒前
完美世界应助归尘采纳,获得30
20秒前
量子星尘发布了新的文献求助10
23秒前
深情安青应助CMM采纳,获得10
32秒前
Maria完成签到,获得积分10
32秒前
54秒前
年轻真好啊完成签到,获得积分10
58秒前
xx关闭了xx文献求助
1分钟前
1分钟前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3960053
求助须知:如何正确求助?哪些是违规求助? 3506261
关于积分的说明 11128558
捐赠科研通 3238254
什么是DOI,文献DOI怎么找? 1789617
邀请新用户注册赠送积分活动 871829
科研通“疑难数据库(出版商)”最低求助积分说明 803056